Retatrutide Research

What Is the TRIUMPH Trial Programme?

UKPWritten & reviewed by William Heath · Editor, UK Peptides research library2 min readLast reviewed 2026-08-224 cited sources

The short answer

TRIUMPH is Eli Lilly's Phase 3 clinical trial programme for retatrutide, enrolling more than 5,800 participants across obesity, type 2 diabetes and cardiovascular populations. TRIUMPH-4 reported first in December 2025, TRIUMPH-1 in May 2026 and TRIUMPH-2 and -3 in July 2026. All pivotal trials reported so far have met their primary endpoints.

Key facts

Sponsor
Eli Lilly and Company
Phase
Phase 3
Total enrolment
More than 5,800 participants
First readout
TRIUMPH-4, December 2025
Pivotal obesity trial
TRIUMPH-1 (NCT05929066), May 2026
Headline result
28.3% mean reduction at 80 weeks (12 mg)
Still outstanding
Maintenance-dosing studies

What the programme covers

TRIUMPH is not a single trial but a set of registrations testing retatrutide in progressively harder populations. TRIUMPH-1 is the pivotal obesity study. TRIUMPH-2 addresses obesity with type 2 diabetes. TRIUMPH-3 addresses severe obesity with established cardiovascular disease. TRIUMPH-4 reported first, in December 2025. Full identifiers, endpoints and enrolment criteria are on ClinicalTrials.gov.

Readout timeline

The programme reported in sequence across roughly eight months. TRIUMPH-4 came first in December 2025. TRIUMPH-1 followed on 21 May 2026 with the headline obesity result. TRIUMPH-2 and TRIUMPH-3 reported together in July 2026, both meeting their primary endpoints in their respective comorbid populations.

  • TRIUMPH-4: first readout, December 2025
  • TRIUMPH-1: pivotal obesity, 21 May 2026, 2,339 randomised
  • TRIUMPH-2: obesity with type 2 diabetes, July 2026
  • TRIUMPH-3: severe obesity with established CVD, July 2026
  • Maintenance-dosing studies: further readouts expected

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

What TRIUMPH-1 reported

Across 2,339 randomised adults, mean weight reduction at 80 weeks was 19.0% on 4 mg, 25.9% on 9 mg and 28.3% on 12 mg, against 2.2% on placebo. A 104-week extension in 532 participants reported 30.3% mean reduction on 12 mg among those with baseline BMI of 35 or above. Gastrointestinal adverse events were common and discontinuation on the 12 mg arm was 11.3% against 4.9% on placebo.

Why maintenance data are the outstanding question

Several further Phase 3 readouts were expected across 2026, including studies of maintenance dosing (what happens when the dose is reduced or stopped after the reduction phase). Weight regain after discontinuation is the unresolved question across the entire incretin class, not just for retatrutide, and it is what the field is waiting on.

Regulatory position

Positive pivotal results do not confer authorisation. Retatrutide remains investigational in every jurisdiction. Lilly has indicated an intended FDA Biologics License Application in the first quarter of 2027. The dose arms described above are facts about a registered trial run under clinical supervision and are not handling guidance.

Frequently asked questions

Where can I find TRIUMPH trial results?

Trials are registered on ClinicalTrials.gov, with topline results issued by Lilly and peer-reviewed publication following database posting.

Have all the TRIUMPH trials reported?

No. The pivotal trials have reported, but further readouts including maintenance-dosing studies were still expected across 2026.

Does TRIUMPH mean retatrutide is approved?

No. It remains investigational everywhere; an FDA filing was signalled for Q1 2027.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and reviewed by

William Heath · Editor, UK Peptides research library

William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.

More Retatrutide Research articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.